FB Mithra Pharmaceuticals Receives Orphan Drug Designation for E4

Free Consultation

877-262-9767

We are dedicated and compassionate

BIRTH INJURY ATTORNEYS

Get Help Today

Mithra Pharmaceuticals Receives Orphan Drug Designation for E4 in Neonatal Encephalopathy

Mithra Pharmaceuticals Receives Orphan Drug Designation for E4 in Neonatal Encephalopathy

Based on promising preclinical results, Mithra Pharmaceuticals received orphan drug designation (a special status for drugs targeted to treat rare conditions) from the European Medicines Agency for estetrol (E4) as a treatment for neonatal encephalopathy (NE). Estetrol is an estrogen steroid hormone produced by the fetal liver during pregnancy that Mithra intends to develop to treat Hypoxic Ischemic Encephalopathy (HIE), a subset of NE. A preclinical study conducted in collaboration with the University of Liège (Belgium) indicated improvements in pathophysiology, general well-being and motor function. Mithra intends to investigate the potential neuroprotective properties of the drug in HIE, which could ultimately lead to clinical development of the drug as a treatment for HIE.

The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.

OK

The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.

OK CANCEL
Real Time Web Analytics